Business
Biopharma Veteran Ivor Macleod Joins SCYNEXIS as Chief Financial Officer
Brings deep industry experience spanning financial and operational roles to support Company and its new strategic direction JERSEY CITY, N.J., Oct. 25, 2022
About this update from Scynexis, Inc.
[{"type":"text","content":"Brings deep industry experience spanning financial and operational roles to support Company and its new strategic direction\nJERSEY CITY, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Ivor Macleod, an accomplished biopharma industry executive, has joined the Company as Chief Financial Officer. “We are thrilled to welcome Ivor to the SCYNEXIS management team,” said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. “Ivor has over 30 years of experience in the life sciences industry and has held multiple financial and operational roles, including supporting research and development, product launch, and subsequent commercialization. Ivor is a strong addition to the management team that will lead SCYNEXIS as we develop additional indications for ibrexafungerp, our groundbreaking first-in-class antifungal for severe, hospital-based indications and pursue a commercial partner for BREXAFEMME® in vulvovaginal candidiasis.” Mr. Macleod joined SCYNEXIS from Athersys, Inc. where he served as Chief Financial Officer since January of 2020. Previously he served as the Chief Financial Officer and Chief Compliance Officer of Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., Prior to joining Eisai, he served as Vice President Finance - Merck Research Labs at Merck & Co., Inc. Before joining Merck, he served from 1998 to 2012 at F. Hoffmann-La Roche, Inc., in various roles, including as North American Chief Financial Officer from 2000 to 2011 and General Manager from 2010 to 2011. “I’m excited to join SCYNEXIS during this important period as the organization shifts its resources to the hospital segment and executes on its critical mission to bring life-saving antifungal treatments to market,” Mr. Macleod said. “As one of the leading companies in the antifungal space, and the only company with a first-in-class antifungal approved in the market in the last 20 years, SCYNEXIS is poised to make a real difference in the lives of patients while pursuing a path to shareholder value creation. I’m thrilled to be a part of the team.” In connection with this appointment, on October 24, 2022, Mr. Macleod was granted an option to purchase 170,000 ...